Outcome of older patients with acute myeloid leukemia in first relapse

American Journal of Hematology

Volumn 88, Issue 9, 2013, Pages 758-764

  Sarkozy, Clémentine ^a,b   Gardin, Claude ^c   Gachard, Nathalie ^d   Merabet, Fathia ^b   Turlure, Pascal ^d   Malfuson, Jean Valère ^e   Pautas, Cécile ^f   Micol, Jean Baptiste ^a   Thomas, Xavier ^g   Quesnel, Bruno ^h   Celli Lebras, Karine ^a   Preudhomme, Claude ^h   Terré, Christine ^b   Fenaux, Pierre ^c   Chevret, Sylvie ^a   Castaigne, Sylvie ^b   Dombret, Hervé ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c UNIVERSITÉ PARIS 13   (France)

^d UNIVERSITY OF LIMOGES   (France)

^e PERCY MILITARY HOSPITAL   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g CENTRE HOSPITALIER LYON SUD   (France)

^h UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; GEMTUZUMAB OZOGAMICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CYTOGENETICS; DRUG SCREENING; FEMALE; HUMAN; KARYOTYPE; LEUKEMIA RELAPSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE;

AGE FACTORS; AGED; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; FEMALE; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84882601957     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23498     Document Type: Article

References (34)

1. Kern W, Schoch C, Haferlach T, Braess J, Unterhalt M, Wörmann B, et al. Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: Relevance of cytogenetic abnormalities. Leukemia 2000;14:226-231.
2. Ferrara F, Morabito F, Latagliata R, Martino B, Annunziata M, Oliva E, et al. Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukemia relapsed from first complete remission. Haematologica 2001;86:814-820.
3. Weltermann A, Fonatsch C, Haas OA, Greinix HT, Kahls P, Mitterbauer G, et al. Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse. Leukemia 2003;18:293-302.
4. Breems DA, Van Putten WLJ, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005;23:1969-1978.
5. Kurosawa S, Yamaguchi T, Miyawaki S, Uchida N, Sakura T, Kanamori H, et al. Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse. Haematologica 2010;95:1857-1864.
6. Ravandi F, Kantarjian H, Faderl S, Garcia-Manero G, O'Brien S, Koller C, et al. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res. 2010;34:752-756.
7. Wagner K, Damm F, Thol F, Göhring G, Görlich K, Heuser M, et al. FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype. Haematologica 2011;96:681-686.
8. Chevallier P, Labopin M, Turlure P, Prebet T, Pigneux A, Hunault M, et al. A new leukemia prognostic scoring system for refractory/relapsed adult acute myelogeneous leukaemia patients: A GOELAMS study. Leukemia 2011;25:939-944.
9. Pautas C, Merabet F, Thomas X, Raffoux E, Gardin C, Corm S, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: Results of the ALFA-9801 study. J Clin Oncol 2010;28:808-814.
10. Itzykson R, Gardin C, Pautas C, Thomas X, Turlure P, Raffoux E, et al. Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: A comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria. Haematologica 2011;96:837-844.
11. Gardin C, Turlure P, Fagot T, Thomas X, Terre C, Contentin N, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: Results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 2007;109:5129-5135.
12. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003;21:4642-4649.
13. ISCN (International System for Human Cytoge- netic Nomenclature). Guidelines for cancer cytogenetics. In Mitelman F, editor. Supplement to an International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1991. pp 1-53.
14. Haferlach C, Mecucci C, Schnittger S, Kohlmann A, Mancini M, Cuneo A, et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood 2009;114:3024-3032.
15. Kaplan EL, Meier P. Non-parametric estimations from incomplete observations. JASA 1958;53:457-481.
16. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. JR Stat Soc A 1972;135:185-206.
17. Cox D. Regression models and life tables. JR Stat Soc B 1972;34:187-220.
18. Guo S, Fraser MW. Propensity score analysis: Statistical methods and applications. In: SAGE Publications, Inc, editor. Advanced Quantitative Techniques in the Social Sciences, vol. 11. Thousand Oaks, California: SAGE Publications; 2010. p 91320.
19. Taksin A-L, Legrand O, Raffoux E, de Revel T, Thomas X, Contentin N, et al. High efficacy and safety profile of fractionated doses of mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: A prospective study of the ALFA group. Leukemia 2007;21:66-71.
20. Farhat H, Reman O, Raffoux E, Berthon C, Pautas C, Kammoun L, et al. Fractionned doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70 years old: A phase 1/2 study of the Acute Leukemia French Association (ALFA). Am J Hematol 2012;87:62-65.
21. Chevallier P, Delaunay J, Turlure P, Pigneux A, Hunault M, Garand R, et al. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. J Clin Oncol 2008;26:5192-5197.
22. Thomas X, Le QH. Treatment of acute myeloid leukemias in the adult in relapse. Bull Cancer 2002;89:795-807.
23. Prebet T, Etienne A, Devillier R, Romeo E, Charbonnier A, D'incan E, et al. Improved outcome of patients with low-and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: Results of a retrospective comparative study. Cancer 2011;117:974-981.
24. Shih LY, Huang CF, Wu JH, Lin TL, Dunn P, Wang PN, et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood 2002;100:2387-2392.
25. Levis M. FLT3/ITD AML and the law of unintended consequences. Blood 2011;117:6987-6990.
26. Chevallier P, Prebet T, Pigneux A, Hunault M, Delaunay J, Perry F, et al. Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin. Leukemia 2010;24:467-469.
27. Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: Results from the CLASSIC I Trial. J Clin Oncol 2012;30:2492-2499.
28. Ravandi F, Estey EH, Appelbaum FR, Lo Coco F, Schiffer CA, Larson RA, et al. Gemtuzumab ozogamicin: Time to resurrect? J Clin Oncol 2012;10:3921-3923.
29. Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomized, open-label, phase 3 study. Lancet 2012;379:1508-1516.
30. Burnett AK, Russell NH, Hills RK, Kell J, Freeman S, Kjeldsen L, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012;30:3924-3931.
31. Tsimberidou AM, Estey E, Cortes JE, Garcia-Manero G, Faderl S, Verstovsek S, et al. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol 2003;52:449-452.
32. Alvarado Y, Tsimberidou A, Kantarjian H, Cortes J, Garcia-Manero G, Faderl S, et al. Pilot study of mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol 2003;51:87-90.
33. Laubach J, Rao AV. Current and emerging strategies for the management of acute myeloid leukemia in the elderly. Oncologist 2008;13:1097-1108.
34. Stasi R, Evangelista ML, Buccisano F, Venditti A, Amadori S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treat Rev 2008;34:49-60.